Last Updated: November 16, 2026

Semaglutide - Generic Drug Details

« Back to Dashboard


What are the generic sources for semaglutide and what is the scope of patent protection?

Semaglutide is the generic ingredient in five branded drugs marketed by Novo and is included in four NDAs. There are forty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for semaglutide
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for semaglutide
Generic Entry Dates for semaglutide*:
Constraining patent/regulatory exclusivity:

TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE

Dosage:

SOLUTION;SUBCUTANEOUS

Generic Entry Dates for semaglutide*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

Generic Entry Dates for semaglutide*:
Constraining patent/regulatory exclusivity:

NEW STRENGTH

Dosage:

SOLUTION;SUBCUTANEOUS

Generic Entry Dates for semaglutide*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for semaglutide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
First Affiliated Hospital of Wenzhou Medical UniversityPHASE2
St. James's Hospital, IrelandPHASE2
Leiden University Medical CenterPHASE3

See all semaglutide clinical trials

Generic filers with tentative approvals for SEMAGLUTIDE
Applicant Application No. Strength Dosage Form
⤷  Start Trial⤷  Start Trial8MG/3MLINJECTION;SOLUTION
⤷  Start Trial⤷  Start Trial4MG/3MLINJECTION;SOLUTION
⤷  Start Trial⤷  Start Trial2MG/3MLINJECTION;SOLUTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for semaglutide
Paragraph IV (Patent) Challenges for SEMAGLUTIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
WEGOVY Tablets semaglutide 25 mg 218316 1 2026-08-28
WEGOVY HD Injection semaglutide 7.2 mg/0.75 mL 215256 1 2026-06-22
WEGOVY Tablets semaglutide 1.5 mg, 4 mg and 9 mg 218316 1 2026-03-11
RYBELSUS Tablets semaglutide 1.5 mg, 4 mg and 9 mg 213051 1 2025-12-11
RYBELSUS Tablets semaglutide 3 mg, 7 mg and 14 mg 213051 1 2024-07-15
OZEMPIC Injection semaglutide 2 mg/3 mL 209637 1 2024-04-11
OZEMPIC Injection semaglutide 8 mg/3 mL 209637 1 2022-12-21
WEGOVY HD Injection semaglutide 0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL 215256 1 2022-10-20
OZEMPIC Injection semaglutide 2 mg/1.5 mL and 4 mg/3 mL 209637 7 2021-12-06

US Patents and Regulatory Information for semaglutide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo RYBELSUS semaglutide TABLET;ORAL 213051-002 Sep 20, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Novo RYBELSUS semaglutide TABLET;ORAL 213051-001 Sep 20, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Novo WEGOVY semaglutide TABLET;ORAL 218316-001 Dec 22, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Novo OZEMPIC semaglutide TABLET;ORAL 213051-005 Dec 9, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novo RYBELSUS semaglutide TABLET;ORAL 213051-002 Sep 20, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-004 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novo OZEMPIC semaglutide TABLET;ORAL 213051-004 Dec 9, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for semaglutide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-004 Jun 4, 2021 8,536,122 ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-004 Oct 6, 2022 RE46363 ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-003 Mar 28, 2022 8,579,869 ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-003 Mar 28, 2022 11,311,679 ⤷  Start Trial
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-001 Jun 4, 2021 8,536,122 ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-004 Oct 6, 2022 10,220,155 ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-003 Mar 28, 2022 RE46363 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for semaglutide

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novo Nordisk A/S Wegovy semaglutide EMEA/H/C/005422Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to Authorised no no no 2022-01-06
Novo Nordisk A/S Ozempic semaglutide EMEA/H/C/004174Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. Authorised no no no 2018-02-08
Novo Nordisk A/S Rybelsus semaglutide EMEA/H/C/004953Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. Authorised no no no 2020-04-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for semaglutide

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1863839 SPC/GB18/023 United Kingdom ⤷  Start Trial PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208
1863839 C201830026 Spain ⤷  Start Trial PRODUCT NAME: OZEMPIC-SEMAGLUTIDA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1251; DATE OF AUTHORISATION: 20180208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1251; DATE OF FIRST AUTHORISATION IN EEA: 20180208
1863839 CR 2018 00019 Denmark ⤷  Start Trial PRODUCT NAME: SEMAGLUTID; REG. NO/DATE: EU/1/17/1251 20180212
1863839 C01863839/01 Switzerland ⤷  Start Trial PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018
1863839 1890018-3 Sweden ⤷  Start Trial PRODUCT NAME: SEMAGLUTIDE; REG. NO/DATE: EU/1/17/1251 20180212
1863839 2018C/016 Belgium ⤷  Start Trial PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839 22/2018 Austria ⤷  Start Trial PRODUCT NAME: SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Semaglutide Market Dynamics and Financial Trajectory: Ozempic, Wegovy and Rybelsus

Last updated: November 16, 2026

Semaglutide has become one of the pharmaceutical industry’s largest growth franchises. Novo Nordisk’s Ozempic, Wegovy and Rybelsus generated approximately DKK 200.5 billion in combined 2024 sales, based on product-level company disclosures. Growth is driven by obesity treatment demand, expanded cardiovascular indications, broader insurance coverage and manufacturing capacity increases. The principal commercial risks are competition from Eli Lilly’s tirzepatide products, reimbursement restrictions, supply normalization, pricing pressure and patent expiry beginning in the United States in 2027.

How large is the semaglutide market?

Semaglutide is marketed in three principal FDA-approved products:

Product Active ingredient Route Primary indication Manufacturer
Ozempic Semaglutide Once-weekly injection Type 2 diabetes and cardiovascular risk reduction in specified patients Novo Nordisk
Wegovy Semaglutide Once-weekly injection Chronic weight management and cardiovascular risk reduction in specified adults with obesity or overweight Novo Nordisk
Rybelsus Semaglutide Once-daily oral tablet Type 2 diabetes Novo Nordisk

Ozempic remains the largest individual semaglutide product by revenue. Wegovy is the faster-growing product because obesity treatment expands the addressable population beyond patients diagnosed with diabetes. Rybelsus provides an oral formulation, although its sales remain materially below the injectable products.

Novo Nordisk reported the following product sales:

Product 2023 sales 2024 sales 2024 growth at constant exchange rates
Ozempic DKK 95.7 billion DKK 120.3 billion Approximately 26%
Wegovy DKK 31.3 billion DKK 58.2 billion Approximately 86%
Rybelsus DKK 18.7 billion DKK 22.1 billion Approximately 24%
Combined semaglutide products DKK 145.7 billion DKK 200.6 billion Approximately 38%

Source: Novo Nordisk annual reports and financial results.[1][2]

The combined figure excludes some related revenue classifications and is not a separate company-reported franchise total. It provides a useful approximation of semaglutide’s commercial scale.

What is driving semaglutide demand?

Obesity treatment is the main expansion market

The obesity market has shifted from a lifestyle-oriented segment to a chronic-disease pharmaceutical category. Wegovy’s demand is supported by:

  • High obesity prevalence in the United States and other developed markets.
  • Substantial average weight loss compared with older anti-obesity medicines.
  • Evidence of cardiovascular risk reduction in adults with obesity and established cardiovascular disease.
  • Greater physician familiarity with GLP-1 therapies.
  • Increased consumer awareness and direct-to-consumer advertising.
  • Broader employer and commercial-insurance coverage, although access remains uneven.

In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke in adults with cardiovascular disease and obesity or overweight.[3] The indication expands the product’s value proposition from weight reduction to risk reduction and may support reimbursement negotiations.

Diabetes demand provides a durable base

Ozempic and Rybelsus benefit from the large and recurring type 2 diabetes market. Patients generally remain on therapy for long periods, creating recurring prescription revenue. Semaglutide also competes favorably on weight loss within the diabetes category, where physicians increasingly consider weight, cardiovascular risk and glycemic control together.

Ozempic’s diabetes franchise is more mature than Wegovy’s obesity franchise. Its growth rate is therefore likely to moderate as market penetration rises and tirzepatide gains share.

Oral semaglutide expands delivery options

Rybelsus is the only approved oral semaglutide product in the United States. It avoids injections but has administration requirements, including dosing on an empty stomach with a limited amount of water and a waiting period before food or other oral medicines.

The oral formulation has strategic value even though Rybelsus sales trail Ozempic and Wegovy. Novo Nordisk is also developing higher-dose oral semaglutide for obesity, which could create a new competitive segment if approved. An oral obesity product could broaden patient acceptance and reduce dependence on injectable manufacturing capacity.

What is the financial trajectory for semaglutide?

Novo Nordisk’s total net sales rose from DKK 232.3 billion in 2023 to DKK 290.4 billion in 2024, an increase of approximately 25% at constant exchange rates.[1][2] Semaglutide products accounted for most of the company’s growth.

Revenue trajectory

Year Novo Nordisk total sales Semaglutide product sales Principal driver
2022 Approximately DKK 177.0 billion Lower than DKK 100 billion combined Ozempic expansion
2023 DKK 232.3 billion Approximately DKK 145.7 billion Ozempic and initial Wegovy scale-up
2024 DKK 290.4 billion Approximately DKK 200.6 billion Wegovy growth and continued Ozempic demand

Revenue growth is likely to remain positive but decelerate from the 2023-2024 rate. The reasons are product maturity, price concessions, increasing competition and potential normalization of supply. Sales volume can continue to increase even when reported revenue growth slows.

Margin and investment effects

Semaglutide has high strategic value because the products are biologic peptide medicines with substantial manufacturing complexity and strong brand recognition. The franchise supports significant gross profit, but Novo Nordisk is also investing heavily in:

  • Fill-finish capacity.
  • Active pharmaceutical ingredient production.
  • New manufacturing sites.
  • Device production for prefilled injection pens.
  • Clinical trials for obesity, cardiovascular disease, liver disease and other metabolic conditions.
  • Commercial infrastructure and market access.

Capacity investment can temporarily pressure capital expenditure and operating margins. Over time, higher utilization should improve the economics of fixed manufacturing assets.

Revenue exposure to the semaglutide franchise

Semaglutide represented roughly 69% of Novo Nordisk’s 2024 total sales when Ozempic, Wegovy and Rybelsus are combined using product-level disclosures. This concentration creates operating leverage but also increases exposure to:

  • FDA labeling or safety developments.
  • Reimbursement decisions.
  • Competitive displacement by tirzepatide.
  • Patent and regulatory challenges.
  • Manufacturing disruptions.
  • Pricing negotiations in the United States.

How does semaglutide compare with tirzepatide?

Tirzepatide is the most important direct competitive threat. Eli Lilly markets Mounjaro for type 2 diabetes and Zepbound for chronic weight management.

Category Semaglutide Tirzepatide
Products Ozempic, Wegovy, Rybelsus Mounjaro, Zepbound
Mechanism GLP-1 receptor agonist GIP and GLP-1 receptor agonist
Obesity approval Wegovy Zepbound
Diabetes approval Ozempic and Rybelsus Mounjaro
Oral product Rybelsus No approved oral product as of the 2024 year-end
Weight-loss positioning Established first-mover franchise Strong efficacy and rapid share gains
Principal commercial advantage Brand scale, cardiovascular data and oral option Clinical efficacy and expanding supply

Clinical trial data from the SURMOUNT-5 study showed greater average weight loss with tirzepatide than with semaglutide in adults with obesity without diabetes, although the trial compared tirzepatide with a specific semaglutide regimen and was sponsored by Lilly.[4] Cross-trial comparisons should not be treated as equivalent to head-to-head evidence.

The competition is likely to shift from simple patient acquisition to:

  • Net price.
  • Insurance formulary placement.
  • Persistence and discontinuation rates.
  • Cardiovascular and renal outcomes.
  • Convenience of administration.
  • Supply reliability.
  • Oral and next-generation formulations.

When does semaglutide lose exclusivity?

The principal U.S. composition-of-matter patent for semaglutide is generally reported to expire in March 2027. Novo Nordisk has additional patents covering formulations, dosing regimens, delivery systems and manufacturing technologies that may extend protection for particular products or create additional barriers after the core compound patent expires.[5]

The practical exclusivity timeline is therefore product-specific:

Exclusivity layer Commercial relevance
U.S. regulatory exclusivity Product-specific and generally shorter than the full patent estate
Core semaglutide patent Reported expiration in March 2027 in the United States
Formulation patents May extend protection for specific oral or injectable compositions
Device and delivery patents May affect pen and administration systems
Method-of-use patents May protect particular patient populations or dosing regimens
Manufacturing patents Can raise the cost and complexity of independent production

Patent expiry does not automatically produce immediate generic competition. An applicant must obtain FDA approval, establish pharmaceutical equivalence or biosimilarity where applicable, address listed patents and obtain sufficient manufacturing capacity.

What is the Orange Book status of Ozempic, Wegovy and Rybelsus?

Ozempic, Wegovy and Rybelsus are FDA-approved products listed in the Orange Book. The listings include patents associated with semaglutide products, including patents directed to active ingredients, formulations, uses and delivery systems.[6]

The Orange Book analysis is complicated by the fact that:

  1. Each product has separate approved labeling.
  2. Patent listings can differ by dosage form and indication.
  3. A patent listed for one product does not automatically block approval of every other semaglutide product.
  4. Regulatory exclusivity and patent expiration are separate legal protections.
  5. The FDA Orange Book can change as patent listings are added, delisted or challenged.

Rybelsus has the most obvious strategic importance for future generic competition because it is an oral small-molecule-style dosage form from an ANDA perspective, although semaglutide itself is a peptide and the regulatory pathway remains technically demanding. Injectable products may face additional device, formulation and manufacturing barriers.

Are there Paragraph IV challenges to semaglutide patents?

As of the 2024 year-end public record, there was no FDA-approved generic Ozempic, Wegovy or Rybelsus. Publicly visible generic-entry activity has focused more heavily on patent disputes involving compounding, unauthorized formulations and alleged trademark or regulatory violations than on an approved ANDA launch.

A Paragraph IV certification could trigger litigation before core patent expiry. The commercial effect would depend on:

  • The specific product and patent challenged.
  • Whether the applicant receives 180-day generic exclusivity.
  • Whether Novo obtains a preliminary injunction.
  • The scope of any settlement.
  • Whether the challenger can manufacture at commercial scale.
  • Whether the product is an ANDA generic or a separate 505(b)(2) application.

No broad, verified settlement framework comparable to major small-molecule generic settlements should be assumed for semaglutide without product-specific court and FDA records.

What patent litigation affects semaglutide?

The most visible legal pressure has involved compounded semaglutide and unauthorized sellers rather than an established generic launch. Novo Nordisk has pursued actions against entities accused of selling compounded or misbranded semaglutide, using trademarks improperly, or distributing products that do not meet FDA requirements.

The legal issues include:

  • Whether compounded semaglutide is permitted under federal compounding law.
  • Whether semaglutide was on the FDA drug-shortage list during the relevant period.
  • Whether compounded products use semaglutide salt forms rather than the active ingredient used in approved products.
  • Trademark infringement involving Ozempic and Wegovy names.
  • Product quality, sterility and labeling claims.
  • Advertising and telehealth distribution practices.

These cases can protect branded demand, but they do not substitute for patent protection. FDA shortage status is especially important because it affects when pharmacies and outsourcing facilities may legally compound copies of commercially available products.[7]

What generic entry risks exist for semaglutide?

Near-term risk: compounded and unauthorized supply

The immediate competitive issue has been nonbranded supply through compounding pharmacies and telehealth platforms. This supply can reduce branded prescription volume, particularly among cash-paying patients who face high list prices or lack insurance coverage.

The risks are regulatory as well as commercial. FDA has warned about dosing errors, counterfeit products and unapproved compounded GLP-1 products.[7][8]

Medium-term risk: tirzepatide substitution

Tirzepatide is a larger commercial threat than conventional generic entry before 2027. Physicians can switch patients without waiting for semaglutide patent expiry, and payers can use formulary management to favor one GLP-1 or incretin product over another.

Longer-term risk: post-2027 generic or follow-on competition

After the core semaglutide patent expires, a successful entrant could target diabetes or obesity indications depending on the application and remaining patents. Commercial entry may still be delayed by:

  • Active formulation patents.
  • Device patents.
  • FDA requirements for peptide characterization and manufacturing.
  • Limited peptide production capacity.
  • Patent litigation.
  • Regulatory exclusivity for newer indications.

What manufacturing barriers protect semaglutide?

Semaglutide manufacturing is a material barrier to entry. The process requires peptide synthesis, purification, formulation, sterile filling and pen assembly for injectable products. Commercial supply also depends on specialized facilities and quality systems.

Novo Nordisk has committed substantial capital to expand production. Lilly is making comparable investments for tirzepatide. Capacity is becoming a competitive asset because demand can exceed available supply even when clinical demand is strong.

Manufacturing barriers are strongest for:

  • High-volume injectable products.
  • Prefilled pen systems.
  • Stable peptide formulations.
  • Products requiring consistent dose escalation.
  • Global supply chains subject to regulatory inspection.

A generic entrant could obtain legal approval yet remain commercially constrained if it cannot secure peptide manufacturing and device capacity.

How does semaglutide’s geographic coverage affect growth?

The United States is the principal profit pool because of high prescription prices and large obesity-treatment demand. Access is constrained by insurance coverage, employer benefit design and federal reimbursement rules.

Europe offers broad patient demand but generally lower net prices. Market expansion depends on national health-technology assessments and reimbursement decisions. Emerging markets provide volume growth but lower pricing and more complex distribution economics.

International expansion is also limited by:

  • Local patent terms.
  • Product registration timelines.
  • Import and manufacturing requirements.
  • Reimbursement budgets.
  • Counterfeit and parallel-trade risks.
  • Local rules governing compounded products.

Novo Nordisk’s international sales growth can diversify the U.S. exposure, but the United States will remain central to franchise profitability.

What is the outlook for semaglutide revenue?

The base-case outlook is continued revenue growth with a lower percentage growth rate than in the 2023-2024 period. The key variables are:

  1. Wegovy penetration among eligible obesity patients.
  2. Reimbursement expansion.
  3. Production capacity.
  4. Tirzepatide market share.
  5. Oral semaglutide development.
  6. Cardiovascular and other outcome-based indications.
  7. Net price reductions.
  8. Patent and regulatory developments.

Novo Nordisk’s 2024 results show that semaglutide remains a major earnings engine. The franchise can continue expanding even as Ozempic matures, provided Wegovy maintains demand and the company converts clinical outcomes into reimbursement.

The most likely financial pattern is:

  • High absolute revenue growth through continued obesity adoption.
  • Slower growth as the U.S. market becomes more competitive.
  • Rising price pressure from payers and Lilly.
  • Increasing capital intensity from manufacturing expansion.
  • Greater legal and regulatory scrutiny of compounded alternatives.
  • A strategic shift toward next-generation oral and multi-pathway incretin therapies.

Key Takeaways

  • Semaglutide products generated approximately DKK 200.6 billion in combined 2024 sales.
  • Ozempic is the largest product; Wegovy is the primary growth engine.
  • Wegovy’s cardiovascular indication broadens its reimbursement and market-access case.
  • Tirzepatide is the leading competitive threat before generic entry.
  • The core U.S. semaglutide patent is generally reported to expire in March 2027.
  • Formulation, device, method-of-use and manufacturing patents may extend practical protection beyond the core patent.
  • No FDA-approved generic semaglutide product was available at the end of 2024.
  • Compounded and unauthorized semaglutide supply creates nearer-term commercial and regulatory pressure.
  • Manufacturing capacity, insurance coverage and net pricing will determine the next phase of revenue growth.
  • Semaglutide remains one of the industry’s most valuable pharmaceutical franchises, but its revenue concentration increases Novo Nordisk’s exposure to competition, reimbursement and exclusivity risk.

FAQs

Is semaglutide expected to remain a blockbuster after 2027?

Yes. Patent expiry may open the market to generic or follow-on competition, but manufacturing complexity, additional patents and strong brand demand could delay broad substitution.

Which semaglutide product has the strongest growth outlook?

Wegovy has the strongest growth outlook because obesity treatment has a larger expansion opportunity than the mature type 2 diabetes market. Rybelsus could gain strategic importance if higher-dose oral semaglutide receives approval for obesity.

Will Medicare cover Wegovy?

Medicare coverage depends on the statutory indication, applicable federal policy and plan rules. The 2024 cardiovascular-risk-reduction approval improves the reimbursement case for qualifying patients, but coverage is not universal.

Can pharmacies legally compound semaglutide?

Compounding is subject to federal and state requirements, including rules tied to drug shortages and pharmacy type. FDA has raised concerns about unapproved formulations, dosing errors and products that do not use the same active ingredient as approved semaglutide products.[7][8]

Is Ozempic more profitable than Wegovy?

Novo Nordisk does not publicly disclose product-level profitability in the same detail as product sales. Ozempic has greater revenue scale and a mature commercial infrastructure, while Wegovy has stronger growth and potentially greater long-term market expansion.

References

  1. Novo Nordisk. (2024). Annual report 2023. https://www.novonordisk.com/investors/annual-report.html

  2. Novo Nordisk. (2025). Annual report 2024. https://www.novonordisk.com/investors/annual-report.html

  3. U.S. Food and Drug Administration. (2024, March 8). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. https://www.fda.gov/news-events/press-announcements

  4. Eli Lilly and Company. (2024). SURMOUNT-5 topline results. https://investor.lilly.com

  5. Novo Nordisk. (2024). U.S. patent information. https://www.novomedlink.com

  6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  7. U.S. Food and Drug Administration. (2024). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers

  8. U.S. Food and Drug Administration. (2024). FDA warns patients and health care professionals about dosing errors with compounded injectable semaglutide products. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.